Skip to main content

Advertisement

Figure 5 | BMC Health Services Research

Figure 5

From: The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients

Figure 5

PAH medication group and PAH diagnosis group average annual health care costs (exploratory analysis). For PAH medication group, differences in costs between baseline and follow-up were statistically significant (p < 0.01) for all categories. For PAH diagnosis group, differences in costs between baseline and follow-up were statistically significant (p < 0.001) for all categories. Bars represent standard deviation.

Back to article page